A Review of the Rationale and Clinical Utilization of α 2 -Adrenoceptor Agonists for the Treatment of Attention-Deficit/Hyperactivity and Related Disorders
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Interest in the potential role for the α2-adrenoceptor agonists clonidine and guanfacine as treatments for attention-deficit/hyperactivity disorder (ADHD) has driven additional clinical studies as well as development of new formulations of these agents. This article reviews the published data that supported United States Food and Drug Administration approval and subsequent clinical use of α2-adrenoceptor agonists in the treatment of ADHD, and identifies promising directions for future research. METHODS: Electronic searches were performed in PubMed through October 2012 using the base terms ADHD or attention deficit hyperactivity disorder and alpha agonists, as well as the following limits: humans, clinical trial, meta-analysis, practice guideline, randomized controlled trial, review, English. The electronic searches were complemented with reference lists from the articles retrieved by informal search of the literature, producing a qualitative review of published, pertinent drug-class preclinical and clinical data. Articles were selected for greater exposition based on hierarchy of evidence (e.g., randomized controlled trials), relevance, and quality of individual studies, as well as generalizability to clinical practice. RESULTS: Results of clinical studies of immediate-release and extended-release formulations of α2-adrenoceptor agonists and basic science investigations of cognitive effects of these drugs are discussed. Studies of both clonidine and guanfacine extended-release formulations as monotherapy and adjunctive therapy with psychostimulants for the treatment of ADHD are also reviewed. CONCLUSIONS: Large, randomized, placebo-controlled clinical trials support the efficacy and safety of α2-adrenoceptor agonists as monotherapy and adjunctive therapy with psychostimulants for the symptomatic treatment of ADHD. Future research could reveal whether there are cognitive benefits associated with this drug class and thus further define the role of α2-adrenoceptor agonists in the treatment of ADHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529 · cited 7×
“Results of a positron emission tomography study with intravenous clonidine in 13 healthy adult male volunteers (Coull et al. 1999) are consistent with the LC-PFC serving a gating function between frontoparietal cortical circuits that mediate attentional states while remaining sensitive to environmental context (i.e.,…”
InfluentialThe locus coeruleus and noradrenergic modulation of cognition
Sara, S. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2573 · Cited by 1,848 · cited 12×
“Results of a positron emission tomography study with intravenous clonidine in 13 healthy adult male volunteers (Coull et al. 1999) are consistent with the LC-PFC serving a gating function between frontoparietal cortical circuits that mediate attentional states while remaining sensitive to environmental context (i.e.,…”
InfluentialPliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.5.564 · Cited by 1,738 · cited 1×
“In clinical settings, ADHD is often comorbid with other externalizing behavior disorders, mood disorders, learning disabilities, and tic disorders (Biederman et al. 1991).”
Self-citationThe Neuropsychopharmacology of Fronto-Executive Function: Monoaminergic Modulation
Robbins, T. W., & Arnsten, A. F. T. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135535 · Cited by 957
Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A., Vijayraghavan, S., Brennan, A., Dudley, A., Nou, E., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.015 · Cited by 672
Treatment of ADHD in children with tics: A randomized controlled trial
The Tourette’s Syndrome Study Group (2002) · Neurology · doi:10.1212/wnl.58.4.527 · Cited by 504
Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
Faraone, S. V., & Buitelaar, J. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0054-3 · Cited by 485 · cited 1×
“Effect sizes have been proposed as a means of comparing results across studies, despite differences in measures and study design (Faraone and Buitelaar 2010).”
(2010) · PsycEXTRA Dataset · doi:10.1037/e664852010-002 · Cited by 456
PLISZKA, S. R., CRISMON, M. L., HUGHES, C. W., CORNERS, C. K., EMSLIE, G. J., JENSEN, P. S., McCRACKEN, J. T., SWANSON, J. M., & LOPEZ, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000215326.51175.eb · Cited by 442
Sallee, F. R., Mcgough, J., Wigal, T., Donahue, J., Lyne, A., & Biederman, J. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318191769e · Cited by 391
Self-citationArnsten, A., Cai, J., & Goldman-Rakic, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-11-04287.1988 · Cited by 391
Arnsten, A. F., & Dudley, A. G. (2005) · Behavioral and Brain Functions · doi:10.1186/1744-9081-1-2 · Cited by 363
Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., Scherer, N., & for the SPD503 Study Group (2008) · Pediatrics · doi:10.1542/peds.2006-3695 · Cited by 317 · cited 9×
“Two short-term (8-and 9-week) pivotal studies (Table 1) (Biederman et al. 2008b; Sallee et al. 2009b) were conducted using GXR as monotherapy.”
InfluentialSallee, F. R., Lyne, A., Wigal, T., & McGough, J. J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0080 · Cited by 306 · cited 9×
“Two short-term (8-and 9-week) pivotal studies (Table 1) (Biederman et al. 2008b; Sallee et al. 2009b) were conducted using GXR as monotherapy.”
InfluentialSelf-citationCoull, J. T., Nobre, A. C., & Frith, C. D. (2001) · Cerebral Cortex · doi:10.1093/cercor/11.1.73 · Cited by 298 · cited 2×
“Studies in healthy normal adults have failed to find a positive effect of a 2-adrenoceptor agonists on cognition for either clonidine (Coull et al. 2001) or guanfacine (Coull et al. 2001; Muller et al. 2005).”
A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder
CONNOR, D. F., FLETCHER, K. E., & SWANSON, J. M. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199912000-00017 · Cited by 297
Self-citationBiederman, J., Melmed, R. D., Patel, A., McBurnett, K., Donahue, J., & Lyne, A. (2008) · CNS Spectrums · doi:10.1017/s1092852900017107 · Cited by 270 · cited 9×
“Two short-term (8-and 9-week) pivotal studies (Table 1) (Biederman et al. 2008b; Sallee et al. 2009b) were conducted using GXR as monotherapy.”
InfluentialSpencer, T. J., Greenbaum, M., Ginsberg, L. D., & Murphy, W. R. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0152 · Cited by 257
CHAPPELL, P. B., RIDDLE, M. A., SCAHILL, L., LYNCH, K. A., SCHULTZ, R., ARNSTEN, A., LECKMAN, J. F., & COHEN, D. J. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199509000-00010 · Cited by 250 · cited 2×
“There are few studies of GUAN-IR in ADHD (Table 1), and all have small sample sizes (Chappell et al. 1995; Hunt et al. 1995; Scahill et al. 2001; Taylor and Russo 2001).”
Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?
SPENCER, T. J., BIEDERMAN, J., HARDING, M., O'DONNELL, D., FARAONE, S. V., & WILENS, T. E. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199611000-00014 · Cited by 238 · cited 1×
“Moreover, psychostimulant effectiveness may be limited or complicated by side effects and tolerability issues (Spencer et al. 1996; Barbaresi et al. 2006).”
Taylor, F. B., & Russo, J. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00015 · Cited by 189 · cited 1×
“There are few studies of GUAN-IR in ADHD (Table 1), and all have small sample sizes (Chappell et al. 1995; Hunt et al. 1995; Scahill et al. 2001; Taylor and Russo 2001).”
Li, B.-M., & Mei, Z.-T. (1994) · Behavioral and Neural Biology · doi:10.1016/s0163-1047(05)80034-2 · Cited by 186
Arnsten, A. F. T., & Contant, T. A. (1992) · Psychopharmacology · doi:10.1007/bf02245302 · Cited by 168 · cited 1×
“In nonhuman primates, guanfacine increased working memory in a dose-dependent manner (Arnsten et al. 1988), and reduced distractibility (Arnsten and Contant 1992).”
Jain, R., Segal, S., Kollins, S. H., & Khayrallah, M. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.11.005 · Cited by 142 · cited 6×
“The first ( n = 236 randomized) was a fixed-dose study of CLON-XR (0.2 or 0.4mg/day in divided doses) as monotherapy (Jain et al. 2008, 2011).”
InfluentialUhlén, S., & Wikberg, J. E. S. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90299-6 · Cited by 141
Clonidine in Child and Adolescent Psychiatry
HUNT, R. D., CAPPER, L., & O'CONNELL, P. (1990) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1990.1.87 · Cited by 127 · cited 2×
“In clinical practice, both clonidine and guanfacine have been used to treat ADHD, both alone and adjunctively with psychostimulants, especially in patients unable to tolerate psychostimulants or those who present clinically with comorbid disorders such as Tourette syndrome or tic disorders, impulsive aggression, or sy…”
Sorkin, E. M., & Heel, R. C. (1986) · Drugs · doi:10.2165/00003495-198631040-00003 · Cited by 106
Connor, D. F., Grasso, D. J., Slivinsky, M. D., Pearson, G. S., & Banga, A. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0119 · Cited by 102 · cited 2×
“2011) and one open-label study of children with symptoms of traumatic stress (Connor et al. 2013) have suggested that cognitive enhancement via a2-adrenoceptor agonists might be beneficial in conditions other than ADHD (e.”
Self-citationConnor, D. F., Findling, R. L., Kollins, S. H., Sallee, F., López, F. A., Lyne, A., & Tremblay, G. (2010) · CNS Drugs · doi:10.2165/11537790-000000000-00000 · Cited by 101
Self-citationLack of effects of guanfacine on executive and memory functions in healthy male volunteers
Müller, U., Clark, L., Lam, M. L., Moore, R. M., Murphy, C. L., Richmond, N. K., Sandhu, R. S., Wilkins, I. A., Menon, D. K., Sahakian, B. J., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0078-4 · Cited by 73 · cited 1×
“Studies in healthy normal adults have failed to find a positive effect of a 2-adrenoceptor agonists on cognition for either clonidine (Coull et al. 2001) or guanfacine (Coull et al. 2001; Muller et al. 2005).”
Kollins, S. H., López, F. A., Vince, B. D., Turnbow, J. M., Farrand, K., Lyne, A., Wigal, S. B., & Roth, T. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0064 · Cited by 53 · cited 9×
“In addition, with the exception of the study by Kollins et al. (2011a), changes in psychostimulant doses were not allowed during these trials, and separate groups treated with mono-therapy with psychostimulants were not included for comparison.”
InfluentialSchulz, K. P., Clerkin, S. M., Fan, J., Halperin, J. M., & Newcorn, J. H. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2893-8 · Cited by 35
Self-citation
Cited by
ADHD: Current Concepts and Treatments in Children and Adolescents
Drechsler, R., Brem, S., Brandeis, D., Grünblatt, E., Berger, G., & Walitza, S. (2020) · Neuropediatrics · doi:10.1055/s-0040-1701658 · Cited by 415
Evidence-based pharmacological treatment options for ADHD in children and adolescents
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107940 · Cited by 293
Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review
Chan, E., Fogler, J. M., & Hammerness, P. G. (2016) · JAMA · doi:10.1001/jama.2016.5453 · Cited by 261
Hirota, T., Schwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.009 · Cited by 161
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Metadata
- Authors
- Sallee, F., Connor, D. F., & Newcorn, J. H.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2013-06
- Volume
- 23
- Issue
- 5
- Pages
- 308-319
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2062137225
- Cited by
- 64
- References
- 33
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.